Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175912 | 0.83 | LMNA (0.49) | ALDH1A1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL4022487 | 0.83 | LMNA (0.49) | ALDH1A1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL5175922 | 0.83 | LMNA (0.49) | ALDH1A1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL31453666 | 0.81 | HSD17B1 (0.45) | HSD17B1HSD17B2ALDH1A1MAPTLMNA | |
| SCHEMBL19890630 | 0.80 | HSD17B1 (0.51) | HSD17B1HSD17B2SIGMAR1SMN1; SMN2LMNA | |
| SCHEMBL1684295 | 0.79 | HSD17B1 (0.57) | HSD17B1HSD17B2ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL30229852 | 0.79 | HSD17B1 (0.57) | HSD17B1HSD17B2ALDH1A1MAPTSIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL28786422 | 0.78 | HSD17B1 (0.55) | HSD17B1HSD17B2ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL21870620 | 0.76 | HSD17B1 (0.54) | HSD17B1HSD17B2ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL2088201 | 0.75 | HSD17B1 (0.57) | HSD17B1HSD17B2MAPTSIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467694-B1 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8658109-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130344489-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8460944-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2467694-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | Roche Diagnostics GmbH (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011020612-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | CA3, CA1, MTCL3 | HSD17B1 4685/4885HSD17B2 4654/4885ALDH1A1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.